Celularity Inc. - SIC # 8010 -

Ticker Exchange SIC # Website Latest Ticker
CELU Nasdaq 8010 www.celularity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celularity Inc.

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - Feb 10th, 2026 6:30 am
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations - Dec 26th, 2025 6:30 am
Celularity Announces Closing of Financing Transactions - Dec 22nd, 2025 2:01 pm
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision - Dec 18th, 2025 12:10 pm
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care - Oct 30th, 2025 6:00 am
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Oct 14th, 2025 6:45 am
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance - Sep 3rd, 2025 6:00 am
Celularity Second Quarter 2025 Earnings: US$1.02 loss per share (vs US$0.30 loss in 2Q 2024) - Aug 31st, 2025 6:47 am
Celularity Receives Nasdaq Notice Regarding Form 10-Q - Aug 22nd, 2025 3:30 pm
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt - Aug 18th, 2025 6:00 am
Retail investors among Celularity Inc.'s (NASDAQ:CELU) largest shareholders, saw gain in holdings value after stock jumped 11% last week - Aug 14th, 2025 4:32 am
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law - Jul 9th, 2025 6:30 am
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies - Jul 1st, 2025 6:30 am
Celularity Announces Chief Financial Officer Transition - Jun 10th, 2025 2:15 pm
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology - Jun 2nd, 2025 6:00 am
Celularity Announces Full Year 2024 Operating and Financial Results - May 9th, 2025 7:15 am
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - Apr 25th, 2025 3:30 pm
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - Apr 14th, 2025 6:00 am
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology - Apr 7th, 2025 6:00 am
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - Feb 25th, 2025 6:00 am